The week in pharma: action, reaction and insight – week to October 3
By Barbara Obstoj-Cardwell
M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program.
Merus to be acquired by Genmab ahead of CRC
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze